Autologous Is Superior to Allogeneic Hematopoietic Cell Transplantation for Acute Promyelocytic Leukemia in Second Complete Remission

Jennifer L. Holter Chakrabarty, Morel Rubinger, Jennifer Le-Rademacher, Hai Lin Wang, Andrew Grigg, George B. Selby, Jeffrey Szer, Jacob M. Rowe, Daniel J. Weisdorf, Martin S. Tallman

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

To identify favored choice of transplantation in patients with acute promyelocytic leukemia (APL) in second complete remission, we studied 294 patients with APL in second complete remission (CR2) receiving allogeneic (n = 232) or autologous (n = 62) hematopoietic cell transplantation (HCT) reported to the Center for International Blood and Marrow Transplantation Research (CIBMTR) from 1995 to 2006, including 155 with pre-HCT PML/RAR status (49% of allogeneic and 66% of autologous). Patient characteristics and transplantation characteristics, including treatment-related mortality, overall survival (OS), and disease-free survival, were collected and analyzed for both univariate and multivariate outcomes. With median follow-up of 115 (allogeneic) and 72 months (autologous), 5-year disease-free survival (DFS) favored autologous with 63% (49% to 75%), compared with allogeneic at 50% (44% to 57%) (P = .10). OS was 75% (63% to 85%) versus 54% (48% to 61%) (P = .002), for autologous and allogeneic transplantation, respectively. Multivariate analysis showed significantly worse DFS after allogeneic HCT (hazard ratio [HR], 1.88; 95% confidence interval [CI], 1.16 to 3.06; P = .011) and age>40 years (HR, 2.30; 95% CI, 1.44 to 3.67; P = .0005). OS was significantly worse after allogeneic HCT (HR, 2.66; 95% CI, 1.52 to 4.65; P = .0006); age>40 (HR, 3.29; 95% CI, 1.95 to 5.54; P < .001), and first complete remission < 12 months (HR, 1.56; 95% CI, 1.07 to 2.26; P = .021). Positive pre-HCT PML-RAR status in 17 of 114 allogeneic and 6 of 41 receiving autologous transplantation did not influence relapse, treatment failure, or survival in either group. The survival advantage for autografting was attributable to increased treatment-related mortality (TRM) in the allogeneic group of 30% compared to 2% in the autologous group, in addition to the added mortality associated with GVHD. We conclude that autologous HCT yields superior OS for APL in CR2. Long-term DFS in autologous recipients, even with minimal residual disease-positive grafts, remains an important subject for further study.

Original languageEnglish (US)
Pages (from-to)1021-1025
Number of pages5
JournalBiology of Blood and Marrow Transplantation
Volume20
Issue number7
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Acute Promyelocytic Leukemia
Cell Transplantation
Disease-Free Survival
Confidence Intervals
Autologous Transplantation
Survival
Transplantation
Mortality
Homologous Transplantation
Residual Neoplasm
Treatment Failure
Multivariate Analysis
Bone Marrow
Transplants
Recurrence
Therapeutics
Research

Keywords

  • Allogeneic transplantation
  • APL
  • Autologous transplantation

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Autologous Is Superior to Allogeneic Hematopoietic Cell Transplantation for Acute Promyelocytic Leukemia in Second Complete Remission. / Holter Chakrabarty, Jennifer L.; Rubinger, Morel; Le-Rademacher, Jennifer; Wang, Hai Lin; Grigg, Andrew; Selby, George B.; Szer, Jeffrey; Rowe, Jacob M.; Weisdorf, Daniel J.; Tallman, Martin S.

In: Biology of Blood and Marrow Transplantation, Vol. 20, No. 7, 01.01.2014, p. 1021-1025.

Research output: Contribution to journalArticle

Holter Chakrabarty, Jennifer L. ; Rubinger, Morel ; Le-Rademacher, Jennifer ; Wang, Hai Lin ; Grigg, Andrew ; Selby, George B. ; Szer, Jeffrey ; Rowe, Jacob M. ; Weisdorf, Daniel J. ; Tallman, Martin S. / Autologous Is Superior to Allogeneic Hematopoietic Cell Transplantation for Acute Promyelocytic Leukemia in Second Complete Remission. In: Biology of Blood and Marrow Transplantation. 2014 ; Vol. 20, No. 7. pp. 1021-1025.
@article{8456388b8c4f434a9f64b25b4c27b586,
title = "Autologous Is Superior to Allogeneic Hematopoietic Cell Transplantation for Acute Promyelocytic Leukemia in Second Complete Remission",
abstract = "To identify favored choice of transplantation in patients with acute promyelocytic leukemia (APL) in second complete remission, we studied 294 patients with APL in second complete remission (CR2) receiving allogeneic (n = 232) or autologous (n = 62) hematopoietic cell transplantation (HCT) reported to the Center for International Blood and Marrow Transplantation Research (CIBMTR) from 1995 to 2006, including 155 with pre-HCT PML/RAR status (49{\%} of allogeneic and 66{\%} of autologous). Patient characteristics and transplantation characteristics, including treatment-related mortality, overall survival (OS), and disease-free survival, were collected and analyzed for both univariate and multivariate outcomes. With median follow-up of 115 (allogeneic) and 72 months (autologous), 5-year disease-free survival (DFS) favored autologous with 63{\%} (49{\%} to 75{\%}), compared with allogeneic at 50{\%} (44{\%} to 57{\%}) (P = .10). OS was 75{\%} (63{\%} to 85{\%}) versus 54{\%} (48{\%} to 61{\%}) (P = .002), for autologous and allogeneic transplantation, respectively. Multivariate analysis showed significantly worse DFS after allogeneic HCT (hazard ratio [HR], 1.88; 95{\%} confidence interval [CI], 1.16 to 3.06; P = .011) and age>40 years (HR, 2.30; 95{\%} CI, 1.44 to 3.67; P = .0005). OS was significantly worse after allogeneic HCT (HR, 2.66; 95{\%} CI, 1.52 to 4.65; P = .0006); age>40 (HR, 3.29; 95{\%} CI, 1.95 to 5.54; P < .001), and first complete remission < 12 months (HR, 1.56; 95{\%} CI, 1.07 to 2.26; P = .021). Positive pre-HCT PML-RAR status in 17 of 114 allogeneic and 6 of 41 receiving autologous transplantation did not influence relapse, treatment failure, or survival in either group. The survival advantage for autografting was attributable to increased treatment-related mortality (TRM) in the allogeneic group of 30{\%} compared to 2{\%} in the autologous group, in addition to the added mortality associated with GVHD. We conclude that autologous HCT yields superior OS for APL in CR2. Long-term DFS in autologous recipients, even with minimal residual disease-positive grafts, remains an important subject for further study.",
keywords = "Allogeneic transplantation, APL, Autologous transplantation",
author = "{Holter Chakrabarty}, {Jennifer L.} and Morel Rubinger and Jennifer Le-Rademacher and Wang, {Hai Lin} and Andrew Grigg and Selby, {George B.} and Jeffrey Szer and Rowe, {Jacob M.} and Weisdorf, {Daniel J.} and Tallman, {Martin S.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.bbmt.2014.03.025",
language = "English (US)",
volume = "20",
pages = "1021--1025",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Autologous Is Superior to Allogeneic Hematopoietic Cell Transplantation for Acute Promyelocytic Leukemia in Second Complete Remission

AU - Holter Chakrabarty, Jennifer L.

AU - Rubinger, Morel

AU - Le-Rademacher, Jennifer

AU - Wang, Hai Lin

AU - Grigg, Andrew

AU - Selby, George B.

AU - Szer, Jeffrey

AU - Rowe, Jacob M.

AU - Weisdorf, Daniel J.

AU - Tallman, Martin S.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - To identify favored choice of transplantation in patients with acute promyelocytic leukemia (APL) in second complete remission, we studied 294 patients with APL in second complete remission (CR2) receiving allogeneic (n = 232) or autologous (n = 62) hematopoietic cell transplantation (HCT) reported to the Center for International Blood and Marrow Transplantation Research (CIBMTR) from 1995 to 2006, including 155 with pre-HCT PML/RAR status (49% of allogeneic and 66% of autologous). Patient characteristics and transplantation characteristics, including treatment-related mortality, overall survival (OS), and disease-free survival, were collected and analyzed for both univariate and multivariate outcomes. With median follow-up of 115 (allogeneic) and 72 months (autologous), 5-year disease-free survival (DFS) favored autologous with 63% (49% to 75%), compared with allogeneic at 50% (44% to 57%) (P = .10). OS was 75% (63% to 85%) versus 54% (48% to 61%) (P = .002), for autologous and allogeneic transplantation, respectively. Multivariate analysis showed significantly worse DFS after allogeneic HCT (hazard ratio [HR], 1.88; 95% confidence interval [CI], 1.16 to 3.06; P = .011) and age>40 years (HR, 2.30; 95% CI, 1.44 to 3.67; P = .0005). OS was significantly worse after allogeneic HCT (HR, 2.66; 95% CI, 1.52 to 4.65; P = .0006); age>40 (HR, 3.29; 95% CI, 1.95 to 5.54; P < .001), and first complete remission < 12 months (HR, 1.56; 95% CI, 1.07 to 2.26; P = .021). Positive pre-HCT PML-RAR status in 17 of 114 allogeneic and 6 of 41 receiving autologous transplantation did not influence relapse, treatment failure, or survival in either group. The survival advantage for autografting was attributable to increased treatment-related mortality (TRM) in the allogeneic group of 30% compared to 2% in the autologous group, in addition to the added mortality associated with GVHD. We conclude that autologous HCT yields superior OS for APL in CR2. Long-term DFS in autologous recipients, even with minimal residual disease-positive grafts, remains an important subject for further study.

AB - To identify favored choice of transplantation in patients with acute promyelocytic leukemia (APL) in second complete remission, we studied 294 patients with APL in second complete remission (CR2) receiving allogeneic (n = 232) or autologous (n = 62) hematopoietic cell transplantation (HCT) reported to the Center for International Blood and Marrow Transplantation Research (CIBMTR) from 1995 to 2006, including 155 with pre-HCT PML/RAR status (49% of allogeneic and 66% of autologous). Patient characteristics and transplantation characteristics, including treatment-related mortality, overall survival (OS), and disease-free survival, were collected and analyzed for both univariate and multivariate outcomes. With median follow-up of 115 (allogeneic) and 72 months (autologous), 5-year disease-free survival (DFS) favored autologous with 63% (49% to 75%), compared with allogeneic at 50% (44% to 57%) (P = .10). OS was 75% (63% to 85%) versus 54% (48% to 61%) (P = .002), for autologous and allogeneic transplantation, respectively. Multivariate analysis showed significantly worse DFS after allogeneic HCT (hazard ratio [HR], 1.88; 95% confidence interval [CI], 1.16 to 3.06; P = .011) and age>40 years (HR, 2.30; 95% CI, 1.44 to 3.67; P = .0005). OS was significantly worse after allogeneic HCT (HR, 2.66; 95% CI, 1.52 to 4.65; P = .0006); age>40 (HR, 3.29; 95% CI, 1.95 to 5.54; P < .001), and first complete remission < 12 months (HR, 1.56; 95% CI, 1.07 to 2.26; P = .021). Positive pre-HCT PML-RAR status in 17 of 114 allogeneic and 6 of 41 receiving autologous transplantation did not influence relapse, treatment failure, or survival in either group. The survival advantage for autografting was attributable to increased treatment-related mortality (TRM) in the allogeneic group of 30% compared to 2% in the autologous group, in addition to the added mortality associated with GVHD. We conclude that autologous HCT yields superior OS for APL in CR2. Long-term DFS in autologous recipients, even with minimal residual disease-positive grafts, remains an important subject for further study.

KW - Allogeneic transplantation

KW - APL

KW - Autologous transplantation

UR - http://www.scopus.com/inward/record.url?scp=84902013723&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902013723&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2014.03.025

DO - 10.1016/j.bbmt.2014.03.025

M3 - Article

C2 - 24691221

AN - SCOPUS:84902013723

VL - 20

SP - 1021

EP - 1025

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 7

ER -